

GLAXOSMITHKLINE ORD GBP0.25

ISIN: **GB0009252882** WKN: **0925288**

Overview

2021/04/09 17:35:03

Price

1,319.60 GBp

Difference  -0.15% (-2.00)

General attributes

ISIN	GB0009252882
Symbol	GSK
Exchange	London Stock Exchange
Currency	GBp
Sector	Chemical / Pharmaceutical / Health
Security type	Stock
Market cap (m)	75,875 EUR
Benchmark	FTSE 100

Market data

Bid (Bid size)	1,319.20 GBp (1,003)
Ask (Ask size)	1,319.40 GBp (194)
Open	1,317.40 GBp
High	1,322.40 GBp
Low	1,304.20 GBp
Close (prev. day)	1,321.60 GBp
VWAP	1,315.43509 GBp
Volume (pcs)	6,415,635
Trading volume	8,439,351,402.00
Number of trades	11,705
Last size	-

Futures and Options

Related Futures	42
Related Options	-

PDF Downloads










Annual report: GLAXOSMITHKLINE ORD GBP0.25 

5Y



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research

on instrument	on sector		
Date		Headline	Download
2021/04/08		Global Equity Ratings	
2021/04/08		Aktienempfehlungen Global	
2021/04/01		Global Equity Ratings	
2021/04/01		Aktienempfehlungen Global	
2021/03/03		Global Equity Ratings	

Details

2021/04/09 17:35:03

Price

1,319.60 GBp

Difference ▼ -0.15% (-2.00)

General attributes

ISIN	GB0009252882
Symbol	GSK
Exchange	London Stock Exchange
Currency	GBp
Sector	Chemical / Pharmaceutical / Health
Security type	Stock
Market cap (m)	75,875 EUR
Benchmark	FTSE 100


Market data

Bid (Bid size)	1,319.20 GBp (1,003)
Ask (Ask size)	1,319.40 GBp (194)
Open	1,317.40 GBp
High	1,322.40 GBp
Low	1,304.20 GBp
Close (prev. day)	1,321.60 GBp
VWAP	1,315.43509 GBp
Volume (pcs)	6,415,635
Trading volume	8,439,351,402.00
Number of trades	11,705
Last size	-

Performance and Risk

	6M	1Y	3Y
Perf (%)	-2.99%	-14.53%	-5.37%
Perf (abs.)	-0.48	-2.63	-0.88
Beta	0.80	0.69	0.69
Volatility	20.62	21.76	23.41

5Y



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

Ø price 5 days Ø volume 5 days (pcs.)	1,301.84 GBp (7,623,659)
Ø price 30 days Ø volume 30 days (pcs.)	1,270.03 GBp (8,297,990)
Ø price 100 days Ø volume 100 days (pcs.)	1,328.47 GBp (8,255,469)
Ø price 250 days Ø volume 250 days (pcs.)	1,464.22 GBp (7,432,075)
YTD High date	1,446.60 GBp (2021/01/07)
YTD Low date	1,190.80 GBp (2021/02/26)
52 Weeks High date	1,748.55 GBp (2020/05/13)
52 Weeks Low date	1,190.80 GBp (2021/02/26)

Arbitrage views

Exchange	Date	Time	Price	Trading volume (mio.)	Number of trades
Xetra	2021/04/09	17:35	15.46 EUR	1.94	212
Tradegate	2021/04/09	22:26	15.56 EUR	1.04	155
Stuttgart	2021/04/09	21:52	15.58 EUR	0.04	12
SIX Swiss Exchange	2020/04/21	17:36	21.50 CHF	0.00	1
Munich	2021/04/09	10:49	15.34 EUR	0.00	2

	09					
London Stock Exchange	2021/04/09	17:35	1,319.60 GBp	8,439.35		11,705
Hanover	2021/04/09	08:04	15.36 EUR	0.00		2
Hamburg	2021/04/09	10:31	15.32 EUR	0.00		2
Frankfurt	2021/04/09	16:37	15.36 EUR	0.05		7
FINRA other OTC Issues	2021/04/09	17:42	18.05 USD	0.01		6
Duesseldorf	2021/04/09	19:30	15.42 EUR	0.00		22
Berlin	2021/04/09	15:03	15.36 EUR	0.00		2

Company profile

Company Logo



Contact Details

GLAXOSMITHKLINE PLC

--

980 Great West Road - TW8 9GS Middlesex

Telefon: 44-20-8047-5000

Fax: 44-20-8047-7807

E-mail: -

PDF Downloads

Annual report: GLAXOSMITHKLINE
ORD GBP0.25

Company Profile

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Members of Management Board

Emma Walmsley	Chairman of Managing Board
Christopher Corsico	Member of Executive Committee
Jon Ellis	Member of Executive Committee
Lon Cardon	Member of Executive Committee
Neil Barnes	Member of Executive Committee
Rab Prinjha	Member of Executive Committee
Amy Altshul	Member of Executive Committee
Brian McNamara	Member of Executive Committee
David Redfern	Member of Executive Committee
Deborah Waterhouse	Member of Executive Committee
Diana Conrad	Member of Executive Committee
James Ford	Member of Executive Committee
Karenann Terrell	Member of Executive

Board of directors

Jonathan Symonds	Chairman of Supervisory Board
Hal Barron	Member of Supervisory Board
Jesse Goodman	Member of Supervisory Board
Laurie Glimcher	Member of Supervisory Board
Charles Bancroft	Member of Supervisory Board
Iain Mackay	Member of Supervisory Board
Judy Lewent	Member of Supervisory Board
Lynn Elsenhans	Member of Supervisory Board
Manvinder Singh Banga	Member of Supervisory Board
Urs Rohner	Member of Supervisory Board
Vivienne Cox	Member of Supervisory Board

	Committee
Kevin Sin	Member of Executive Committee
Luke Miels	Member of Executive Committee
Marc Jones	Member of Executive Committee
María Cristina Henríquez de Luna Basagoiti	Member of Executive Committee
Maya Martinez-Davis	Member of Executive Committee
Nick Hirons	Member of Executive Committee
Philip Thomson	Member of Executive Committee